✦ LIBER ✦

Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy

✍ Scribed by Benz, J R; Black, H R; Graff, A; Reed, A; Fitzsimmons, S; Shi, Y

Book ID: 110047855
Publisher: Nature Publishing Group
Year: 1998
Tongue: English
Weight: 58 KB
Volume: 12
Category: Article
ISSN: 0950-9240
DOI: 10.1038/sj.jhh.1000718

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Doxazosin in combination with atenolol i

Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial

✍ M. Searle; R. Dathan; S. Dean; C. C. Christensen; A. Westheim 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 184 KB

Doxazosin (mean dose 11 mg) given once daily in combination with 100 mg atenolol (n = 44) was compared with placebo and atenolol (n = 43) in a double-blind, multicenter study in patients with mild to moderate essential hypertension. In the atenolol/doxazosin-treated group, standing blood pressure si

Double-blind trial comparing guanfacine

Double-blind trial comparing guanfacine and methyldopa in patients with essential hypertension

✍ A. J. Bune; J. P. Chalmers; J. R. Graham; P. R. C. Howe; M. J. West; L. M. H. Wi 📂 Article 📅 1981 🏛 Springer 🌐 English ⚖ 621 KB

A randomised, placebo-controlled, double

A randomised, placebo-controlled, double-blind, crossover study of losartan and enalapril in patients with essential hypertension

✍ Fagard, R; Lijnen, P; Pardaens, K; Thijs, L; Vinck, W 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 142 KB

Single and divided daily dose piretanide

Single and divided daily dose piretanide in the treatment of uncomplicated essential hypertension: A double-blind comparison with a combination of hydrochlorothiazide and amiloride

✍ M. Verho; B. Rangoonwala; W. Dols 📂 Article 📅 1985 🏛 Springer 🌐 English ⚖ 624 KB

Rituximab in patients with primary progr

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro

Efficacy and safety of initial combinati

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study

✍ R. Gomis; R.-M. Espadero; R. Jones; H. J. Woerle; K. A. Dugi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 849 KB